Jonathan W. Goldman, MD

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin for the treatment of locally advanced or metastatic NSCLC with c-MET overexpression.

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Jonathan W. Goldman, discusses the impact of liquid biopsies in lung cancer.

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.